|
|
SPOT ON
|
|
Post-marketing trials without tangible benefit
|
|
|
NEW ON THE MARKET
|
|
Anti-interleukin-5 antibody reslizumab (CINQAERO) for severe eosinophilic asthma
|
|
|
THERAPY FROM A CRITICAL VIEWPOINT
|
|
Delirium in palliative care: neuroleptics worse than placebo
Tapentadol (PALEXIA, YANTIL): What's new?
|
|
|
IN BRIEF
|
|
Migraine prevention in children: is placebo the best medicine?
Death following overdose of colchicine - the package size of the drop formulation is to be limited
France: zolpidem (STILNOX, generics) -narcotic prescription required
Glucosamine and chondroitin in osteoarthritis without benefit in yet another study
|
|
|
CURRENT ADR NETWORK REPORT
|
|
Urticaria with apixaban (ELIQUIS)
|
|
|
SIDE EFFECTS
|
|
Malformations with hydroxyethylrutoside (e.g. VENORUTON)?
Fatalities with selexipag (UPTRAVI) in pulmonary hypertension
|
|
Rivaroxaban (XARELTO): agranulocytosis and STEVENS-JOHNSON syndrome
|
|
|
e a-t IN THE INTERNET
|
|
Elbasvir plus Grazoprevir (ZEPATIER) for hepatitis C
Amputations with SGLT2 inhibitors
Once more: anaphylactic reactions with chlorhexidine
|
|